Genetics In Neurodegenerative Disorders

Genetic mutations are increasingly being recognised as contributing to symptoms associated with neurodegenerative disorders such as Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease. While they may not account for all cases, they are estimated to be responsible for about 10-15% of cases of Parkinson’s disease, 20-25% of cases of Huntington’s disease, and 10-20% of cases of Alzheimer’s disease. Most recently, scientists have identified the APOE gene, which is associated with increased risk of developing late onset Alzheimer’s disease. It’s now recognized that this gene can be inherited from a parent, making the risk of developing neurodegenerative disorders higher among those who have such a parent. In addition to the APOE gene, mutations in a variety of other genes, including α-Synuclein, Parkin, LRRK2, and VPS35, have been associated with Parkinson’s disease. Gamma-secretase may be the target gene for mutations leading to Alzheimer’s, while expanded CAG repeats on Huntingtin have been linked to Huntington’s disease. While the exact mechanisms by which these mutations lead to disease is poorly understood, it is believed that they may lead to altered or impaired functioning of vital systems and proteins that regulate neuronal health and death. Scientists are now trying to understand the part genetics plays in the onset and progression of neurodegenerative disorders. They are studying the interactions between genetic and environmental factors, as well as gene-gene interactions, which may alter the way in which the genes are expressed. This type of research requires large-scale genetic sequencing efforts and statistical analysis of patient samples, which can be expensive and time-consuming. Despite this, the hope is that further insights into genetic contributions to neurodegenerative disorders can lead to improved clinical outcomes for patients.